Navigation Links
Peripheral Artery Disease (PAD) Patent Granted to Dimera
Date:8/11/2009

PORTLAND, Ore., Aug. 11 /PRNewswire/ -- The U.S. Patent and Trade Office (USPTO) plans to announce patent award approval on August 11 to Dimera Incorporated for treatment of symptoms of Peripheral Arterial Disease (PAD), which is alternatively known as Peripheral Vascular Disease (PVD).

"Method and Kit for reducing the symptoms of peripheral vascular disease," (Number 7572780) covers the period August 11, 2009 through July 28, 2024. Dimera President, Prof. R. Kent Hermsmeyer, said, "We are pleased to announce perhaps the most important of the Dimera patents to date. Dimera plans to further optimize our success in demonstrating the virtues of our advanced transdermal strategy that we have extensively documented in primates to greatly extend normal function in the peripheral circulation."

Hermsmeyer explains that, "The loss of normal function of blood vessels explains deterioration of the peripheral circulation, and that decline in function with age now appears to be preventable. If women and men at the peak of cardiovascular health used our discovery to counter the avoidable fall in essential molecular function - which we have identified and mapped - then the expectation of reduced mobility and even disability with advancing age might be dispelled. Rather than addressing only the symptoms of peripheral vascular disease, Dimera has taken the demanding - but arguably more powerful - approach that demands discovery and understanding of the underlying molecular mechanism at the gene level."

The significance of this patent is one of the premiere successful translations of science - cell and molecular biology - to clinically effective medicine.

About Dimera

Founded by world-renown researchers in 1997 as a pure R&D biotech, Dimera (www.dimera.net) has evolved into a drug development firm specializing in cardiovascular and smooth muscle d
'/>"/>

SOURCE Dimera Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. CeNeRx BioPharma Awarded New Patent for its Innovative Compounds That Selectively Target Peripheral Cannabinoid Receptors
2. Results From Phase 2 Clinical Study of 6R-BH4 in Peripheral Arterial Disease Not Statistically Significant
3. ev3 Inc. Receives FDA Clearance to Market EverCross and NanoCross Peripheral Angioplasty Balloons
4. Aortic Stent Grafts Will Boost Canadian and Japanese Peripheral Vascular Markets
5. Peripheral Vascular Device Market Insights Webinar
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
8. Vermillion Biomarker Panel Potential Aid in the Diagnosis of Peripheral Artery Disease
9. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
10. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
11. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  EMD Serono today announced the US biopharmaceutical ... , appointed Alise Reicin , MD, ... Development.  Dr. Reicin brings extensive research and early/late ... Immunology. She is an accomplished pharmaceutical executive with ... President in various capacities across R&D at MSD ...
(Date:4/16/2015)... and MENLO PARK, Calif. , April ... DMPI) (DelMar and the Company), a biopharmaceutical company focused ... orphan drug indications, today announced that the Mayo ... clinical trial site for the ongoing, multicenter Phase I/II ... (GBM), the most common and deadly form of human ...
(Date:4/16/2015)... 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ... DCVax® personalized immune therapies for cancer, announced today ... Cancer Immunotherapy Index (LCINDX), a professional index recently ... field within the biotechnology space.  ... companies" in the immunotherapy space, including 6 big ...
(Date:4/16/2015)... Tex. (PRWEB) April 16, 2015 ... chain management systems for highly regulated industries, is ... been name a monthly columnist for Cold Chain ... ( http://www.coldchainiq.com ). His column titled, Global Cold ... chain information for today’s life sciences, pharmaceutical and ...
Breaking Biology Technology:Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 2Modality Solutions Gary Hutchinson Named Columnist for Cold Chain IQ 3
... April 12, 2011 Reportlinker.com announces that a new ... Biomarker Partnering Terms and Agreements ... The Biomarker Partnering Terms and Agreements report ... partnering deals and agreements entered into by the worlds ...
... April 11, 2011 Shrink Nanotechnologies, Inc. ("Shrink") (OTC ... that it has executed a binding letter of intent ... biomedical instrumentation and microfluidics company with global distribution for ... The transaction highlights are: Shrink ...
... Dyadic International, Inc. ("Dyadic") (OTC Pink: DYAI), ... development, manufacture and sale of enzyme and protein ... industries, today announced that its President and Chief ... Advanced Biofuels Leadership Conference taking place from April ...
Cached Biology Technology:Reportlinker Adds Biomarker Partnering Terms and Agreements 2Reportlinker Adds Biomarker Partnering Terms and Agreements 3Reportlinker Adds Biomarker Partnering Terms and Agreements 4Reportlinker Adds Biomarker Partnering Terms and Agreements 5Reportlinker Adds Biomarker Partnering Terms and Agreements 6Reportlinker Adds Biomarker Partnering Terms and Agreements 7Reportlinker Adds Biomarker Partnering Terms and Agreements 8Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 2Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 3Shrink Nanotechnologies Signs Binding Letter of Intent to Acquire 100% of Hawaii-Based Nanopoint, Inc. 4Dyadic International to Present at Advanced Biofuels Leadership Conference 2
(Date:3/23/2015)... OXFORD, Conn. , Mar. 23, 2015 NXT-ID, Inc. ... authentication company focused on the growing mobile commerce market, announces ... a new advertising campaign on CNBC television starting March 30 ... ads will commence airing in New York ... Executive Officer said: "We are excited about our new ad ...
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ... - Global Strategic Business Report" report to their offering. ... Biometrics in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Latin America . Annual estimates ...
(Date:3/17/2015)... 17, 2015 Emotient, the leader in ... announced general availability of Emotient Analytics , ... analysis of facial expressions. The system analyzes videos ... products and services. It delivers audience response metrics ... - as derived from facial evidence of emotional ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 2New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 3New Emotient Web Service Measures Audience Response Using On-Demand Facial Expression Analysis 4
... discovery made by researchers at the Institut de recherches ... Di Noia, Director of the Mechanisms and Genetic Diversity ... Journal of Experimental Medicine . The team identified a ... for the therapy of some types of lymphoma and ...
... State University are developing a cost-effective electronic monitoring system ... critical coastal ecosystems by allowing users to track water-quality ... support from a National Science Foundation (NSF) grant. ... to monitor environmental conditions in the Chesapeake Bay, the ...
... London, UK (November 1, 2010) In April 2010, ... on the conclusion that the current missile defense systems will ... of nuclear-armed combat. Now research in the Bulletin of ... have not been tested against real-world threats and would not ...
Cached Biology News:A discovery could be important for the therapy of lymphoma and leukemia 2Researchers developing real-time electronic monitoring for coastal waters 2US nuclear safety claim is a 'dangerous fantasy' 2US nuclear safety claim is a 'dangerous fantasy' 3